1
|
Alonso Fernandez De Gatta M, Martin Garcia A, Diez-Campelo M, Martin-Garcia AC, Diaz-Pelaez E, Lopez Cadenas F, Jimenez Solas T, Sanchez PL. P4684Myocardial deformation with cardiac magnetic resonance imaging feature tracking analysis in patients with transfusion-dependent myelodysplastic syndrome. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - A Martin Garcia
- Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain
| | - M Diez-Campelo
- Hospital Clínico Universitario, Hematology Department, Salamanca, Spain
| | - A C Martin-Garcia
- Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain
| | - E Diaz-Pelaez
- Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain
| | - F Lopez Cadenas
- Hospital Clínico Universitario, Hematology Department, Salamanca, Spain
| | - T Jimenez Solas
- Hospital Clínico Universitario, Hematology Department, Salamanca, Spain
| | - P L Sanchez
- Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain
| | | |
Collapse
|
2
|
Alonso Fernandez De Gatta M, Martin Garcia A, Diez-Campelo M, Diaz-Pelaez E, Barreiro-Perez M, Lopez-Cadenas F, Martin-Garcia A, Jimenez-Candil J, Gallego-Delgado M, Calvo-Martin I, Macias De Plasencia G, Garde-Pellejero B, Del Canizo Fernandez-Roldan C, Sanchez P. P2442Assessment of iron overload and cardiac disease in patients with transfusion-dependent myelodysplastic syndromes with cardiac magnetic resonance new sequences. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Diez-Campelo M, Blanco M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz G, Florensa L. Calculating IPSS-R by Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in MDS with Erythroid Predominance. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30351-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Muntion S, Ramos TL, Diez-Campelo M, Roson B, Misiewicz-Krzeminska I, Sanchez-Abarca L, Preciado S, Sarasquete M, Gonzalez M, Sanchez-Guijo F, del Cañizo M. 29 MICROVESICLES/EXOSOMES DERIVED FROM BONE MARROW MESENCHYMAL STROMAL CELLS (MSC) ARE INVOLVED IN THE INTERCELLULAR COMMUNICATION BETWEEN HEMATOPOIETIC CELLS AND BM MICROENVIRONMENT IN MDS PATIENTS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30030-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Sanz G, de Paz R, Bernal T, Bargay J, Montesinos P, Diez-Campelo M, del Cañizo C. 118 A PHASE 2 STUDY OF AZACITIDINE AND EPOETIN-BETA IN UNTREATED RBC-TRANSFUSION DEPENDENT LOWER-RISK MDS PATIENTS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30119-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Ramos F, Robledo C, Izquierdo-Garcia F, Vilela DS, Benito R, Fuertes M, Insunza A, Barragan E, Del Rey M, Tormo M, Salido E, Zamora L, Pedro C, Sanchez-del-Real J, Diez-Campelo M, Del Cañizo C, Sanz G, Hernandez-Rivas J. 244 MYELOFIBROSIS (MF) AS A PROGNOSTIC TOOL FOR OVERALL SURVIVAL IN MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE EVALUATION INCLUDING MUTATIONAL ANALYSIS BY NEXT GENERATION SEQUENCING (NGS). Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30245-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Muntión S, Sánchez-Guijo FM, Carrancio S, Villarón E, López O, Diez-Campelo M, San Miguel JF, del Cañizo MC. Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use. Transfus Med 2012; 22:122-7. [PMID: 22296109 DOI: 10.1111/j.1365-3148.2012.01134.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE The aim of this study was to optimise the yield of metaphases in mesenchymal stromal cells (MSC) in vitro cultures and to study the karyotype of MSC expanded in good manufacturing practice (GMP) conditions for clinical use. BACKGROUND MSC are being increasingly used in clinical trials for a number of diseases. Biosafety demonstration in all cases is mandatory. Unfortunately, current standard karyotyping methods fail to obtain enough number of evaluable metaphases. METHODS AND MATERIALS In the present work, to optimise the yield of metaphases in MSC expanded in vitro, we have tested several conditions by modifying colcemid concentration (we have tested 0.01, 0.05 and 0.1 µg mL(-1) ) and exposure time (during 5, 15 and 24 h). We further applied these optimised conditions to 61 MSC expansions in GMP conditions for clinical use. RESULTS Our results show that the highest number of metaphases was obtained when MSC were incubated with 0.05 µg mL(-1) of colcemid overnight (15 h), compared to the remaining experimental conditions. In most cases (59/61 cases) enough number of metaphases was obtained. And what is more relevant, only in one case a karyotypic abnormality was found (trisomy of chromosome 10), and cells were subsequently discarded for clinical use. CONCLUSION We describe here an optimal method to obtain enough number of metaphases for karyotype analysis of in vitro expanded MSCs, what is essential for their clinical use in cell therapy programmes.
Collapse
Affiliation(s)
- S Muntión
- Centro en red de Medicina Regenerativa y Terapia Celular de Castilla y León and Red Nacional de Terapia Celular (Tercel, ISCIII), Salamanca, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
del Rev M, O'Hagan K, Lumbreras E, Aibar S, Dellett M, Diez-Campelo M, de las Rivas J, Mills K, Hernández J. 235 An integrative analysis of methylation and gene expression profiling in low-risk myelodysplastic syndromes (MDS). Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70237-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Sanchez-Garcia J, Del Cañizo C, Such E, Nomdedeu B, Luño E, De Paz R, Xicoy B, Valcarcel D, Sierra A, Marco V, Garcia M, Osorio S, Tormo M, Bailen A, Cervero C, Torres-Gomez A, Ramos F, Diez-Campelo M, Belkaid M, Arrizabalaga B, Azaceta G, Bargay J, Arilla M, Caballero M, Falantes J, Sanz G. 64 A retrospective time-dependent comparative analysis of the impact of lenalidomide on outcomes in lower risk MDS with chromosome 5q deletion. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70066-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Ramos F, Pedro C, de Paz R, Insunza A, Tormo M, Diez-Campelo M, Xicoy B, Salido E, Sanchez-Del-Real J, Arenillas L, Florensa L, Sole F, Sanz G. 315 Prognostic impact of performance status and comorbidity on the overall survival of patients with myelodysplastic syndromes: A prospective evaluation. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70317-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, Hernández-Campo P, Lopez-Holgado N, Diez-Campelo M, Barbado MV, Perez-Simon JA, Hernández-Rivas JM, San-Miguel JF, del Cañizo MC. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome. Leukemia 2009; 23:664-72. [DOI: 10.1038/leu.2008.361] [Citation(s) in RCA: 99] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
12
|
Tabera S, Perez-Simon JA, Diez-Campelo M, Sanchez-Abarca LI, Blanco B, Lopez A, Benito A, Ocio E, Sanchez-Guijo FM, Canizo C, San Miguel JF. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008; 93:1301-9. [DOI: 10.3324/haematol.12857] [Citation(s) in RCA: 203] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
13
|
Arcos M, Diez-Campelo M, Caballero M, Vidan J, Perez-Simon J, Vazquez L, Canizo M, Castilla C, Mateos J, Lopez O, Perez E, Encinas C, Graciani I, San Miguel J. Pentostatin in refractory acute and chronic GVHD. A single center experience. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Diez-Campelo M, Perez-Simon J, Castilla C, Sanchez-Guijo F, Caballero M, Canizo M, Vazquez L, San Miguel J. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft versus host disease (GVHD). Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.111] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16:1423-31. [PMID: 12145680 DOI: 10.1038/sj.leu.2402550] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2001] [Accepted: 10/22/2001] [Indexed: 11/09/2022]
Abstract
Since graft-versus-leukemia (GVL) is the main weapon for disease eradication after reduced intensity conditioning (RIC) allogeneic SCT, the availability of sensitive and specific techniques to monitor changes in tumor load after transplant are especially helpful. These minimal residual disease techniques would allow an early intervention in the event of low tumor burden, for which immunotherapy is highly effective. Some authors have found an association between persistence of MRD, mixed chimerism and risk of relapse. Nevertheless, data from the literature remain contradictory and further correlations should be established, especially in RIC transplants. In this study we have analyzed the impact of MRD and chimerism monitoring on the outcome of 34 patients undergoing RIC allogeneic SCT who were considered poor candidates for conventional transplantation due to advanced age or other concurrent medical conditions. At day +100 25 (75%) patients reached complete remission (CR), there were five (15%) partial responses and three patients progressed. Incidence of grade 2-4 aGVHD and extensive cGVHD were 35% and 58%, respectively. Sixteen percent of patients developing aGVHD relapsed as compared to 47% in those without aGVHD (P = 0.03) and also 10% of patients developing cGVHD relapsed as compared to 50% relapses in those without cGHVD (P = 0.03). Four patients (12%) died due to early (n = 1) and late (n = 3) transplant-related mortality. After a median follow-up of 15 months, 24 out of the 34 patients remain alive. Projected overall survival and disease-free survival at 3 years are 68% and 63%, respectively. Early chimerism analysis showed 67% of patients with complete chimerism (CC) in bone marrow (BM), 86% in peripheral blood (PB), 89% in granulocytes and 68% in T lymphocytes. On day +100, these figures were 68%, 79%, 90% and 73%, respectively, and on day +180 there were 83% patients with CC in BM, 100% in PB, 100% in granulocytes and 100% in T lymphocytes. We observed a trend to a higher incidence of relapse in patients with mixed chimerism (MC) as compared to patients with CC. MRD monitoring by flow cytometry and/or RT-PCR analysis was performed in 23 patients. MRD assessment on days +21 to +56 after transplant allowed identification of patients at risk of relapse. In this sense, seven out of 12 patients (58.3%) who had positive MRD on days +21 to +56 relapsed as compared to none out of 11 patients who had negative MRD (P = 0.002). Of the seven patients with criteria to monitor MRD who relapsed after transplant, all but one remained MRD positive until relapse. By contrast, 10 patients remained MRD negative and all of them are in continuous CR. In nine additional patients, persistence of MRD or mixed chimerism was observed after transplant and withdrawal of cyclosporin with or without DLI was performed. Only two out of these nine patients relapsed. MRD clearance was preceded by CC and GVHD. In conclusion, in our study we found that RIC allogeneic transplantation can be used in patients considered poor candidates for conventional transplantation due to advanced age or other concurrent medical conditions with both low toxicity and low transplant-related mortality. Simultaneous studies of both chimerism and MRD are a useful tool in order to predict risk of relapse in patients undergoing RIC transplants and so can be helpful for individualizing treatment strategies after transplant.
Collapse
Affiliation(s)
- J A Pérez-Simón
- Servicio de Hematología, Hospital Clínico Universitario de Salamanca, Salamanca, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|